Names | |
---|---|
Preferred IUPAC name
2-Ethyl-3-methylpentanamide[1] | |
Identifiers | |
3D model (JSmol)
|
|
ChEMBL | |
ChemSpider | |
ECHA InfoCard | 100.021.849 |
EC Number |
|
KEGG | |
MeSH | valnoctamide |
PubChem CID
|
|
RTECS number |
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C8H17NO | |
Molar mass | 143.230 g·mol−1 |
Appearance | White crystals |
log P | 1.885 |
Pharmacology | |
N05CM13 (WHO) | |
| |
Pharmacokinetics: | |
94% | |
Hepatic | |
10 hours | |
Hazards | |
GHS labelling: | |
Warning | |
H302 | |
Lethal dose or concentration (LD, LC): | |
LD50 (median dose)
|
760 mg kg−1 (oral, rat) |
Related compounds | |
Related alkanamides
|
Valpromide |
Related compounds
|
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Valnoctamide (INN, USAN) has been used in France as a sedative-hypnotic since 1964.[2] It is a structural isomer of valpromide, a valproic acid prodrug; unlike valpromide, however, valnoctamide is not transformed into its homologous acid, valnoctic acid, in vivo.[3]